Spots Global Cancer Trial Database for castrate resistant prostate cancer
Every month we try and update this database with for castrate resistant prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TT-702 in Patients With Advanced Solid Tumours. | NCT05272709 | Advanced Solid ... | TT-702 Darolutamide | 16 Years - | Cancer Research UK | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | NCT05570994 | Metastatic Cast... Prostate Cancer... Castrate Resist... | 177Lu HTK03170 68Ga-HTK03149 | 18 Years - | British Columbia Cancer Agency | |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | NCT00564928 | Prostate Cancer Prostatic Neopl... Cancer of the P... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | NCT04541225 | Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob... | NUV-422 | 18 Years - | Nuvation Bio Inc. | |
| Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01516762 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA | NCT04319783 | Advanced Prosta... Cancer of Prost... PSA Castrate Resist... | Darolutamide Radiotherapy | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | NCT04335682 | Metastatic Pros... Prostate Cancer... Prostate Cancer Castrate Resist... | Darolutamide Enzalutamide | 18 Years - | Alliance Foundation Trials, LLC. | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01516762 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer | NCT00564928 | Prostate Cancer Prostatic Neopl... Cancer of the P... | IPI-504 | 18 Years - | Infinity Pharmaceuticals, Inc. | |
| Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases | NCT02135484 | Prostate Cancer | Alpharadin | 18 Years - | M.D. Anderson Cancer Center | |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers | NCT05582031 | Anal Squamous C... Colorectal Neop... Soft Tissue Sar... Malignant Pleur... Small Cell Lung... Castrate Resist... Neuroendocrine ... Gastroenteropan... | Regorafenib in ... | 18 Years - | Translational Research in Oncology | |
| Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | NCT05627752 | Prostate Cancer Castrate Resist... | Enzalutamide 40... Docetaxel injec... | 18 Years - 75 Years | Zhongnan Hospital | |
| PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | NCT03460977 | Castration Resi... Small Cell Lung... Follicular Lymp... | PF-06821497 | 18 Years - | Pfizer | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| TKI258 in Castrate Resistant Prostate Cancer | NCT00831792 | Prostate Cancer | TK1258 | - | M.D. Anderson Cancer Center | |
| Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients | NCT02376296 | Prostate Cancer | docetaxel Blood draws | 18 Years - | Saladax Biomedical, Inc. | |
| Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer | NCT01313559 | Castrate Resist... Chemotherapy Na... Prostate Cancer | Pasireotide Everolimus Laboratory biom... | 18 Years - | Thomas Jefferson University | |
| Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer | NCT01599793 | Bone Metastases Castrate-resist... Recurrent Prost... Stage IV Prosta... | cabozantinib laboratory biom... magnetic resona... | - | University of Chicago | |
| TKI258 in Castrate Resistant Prostate Cancer | NCT00831792 | Prostate Cancer | TK1258 | - | M.D. Anderson Cancer Center | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. | |
| TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | NCT04969315 | Renal Cell Canc... Castrate Resist... Non Small Cell ... Head and Neck S... | TT-10 | 18 Years - | Portage Biotech | |
| Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients | NCT05156372 | Prostate Cancer... Castrate Resist... Metastatic Pros... Metastatic Pros... | High Intensity ... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | NCT02950064 | Pancreatic Neop... Ovarian Neoplas... Breast Neoplasm... Prostatic Neopl... | BTP-114 | 18 Years - | Placon Therapeutics | |
| Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer | NCT05766371 | Castrate Resist... Metastatic Cast... Prostate Cancer Prostate Carcin... | Pembrolizumab 177Lu-PSMA-617 | 18 Years - | University of California, San Francisco | |
| Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer | NCT04737109 | Castrate Resist... | Ipatasertib Darolutamide Androgen Depriv... | 18 Years - | Big Ten Cancer Research Consortium | |
| 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | NCT05570994 | Metastatic Cast... Prostate Cancer... Castrate Resist... | 177Lu HTK03170 68Ga-HTK03149 | 18 Years - | British Columbia Cancer Agency | |
| 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer | NCT04689828 | Prostatic Neopl... | 177Lu-PSMA-617 68Ga-PSMA-11 ARDT Best supportive... | 18 Years - | Novartis | |
| Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors | NCT05488548 | Castrate Resist... NUT Carcinoma | EP31670 | 18 Years - | Epigenetix, Inc. | |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | NCT04541225 | Glioma Glioma, Maligna... Glioma, Mixed Glial Cell Tumo... Breast Cancer Breast Carcinom... Cancer of Breas... Cancer of the B... Breast Tumor Malignant Tumor... Advanced Breast... Advanced Breast... Metastatic Brea... Metastatic Brea... Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration-resi... Castration Resi... Glioblastoma Recurrent Gliob... | NUV-422 | 18 Years - | Nuvation Bio Inc. | |
| Checkpoint Inhibitors and SBRT for mCRPC | NCT05655715 | Prostate Cancer... Castrate Resist... Metastatic Cast... Prostate Cancer... | Stereotactic bo... Ipilimumab Inje... Nivolumab Injec... Biopsies | 18 Years - | Herlev and Gentofte Hospital | |
| Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01618370 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone | NCT04296578 | Prostate Cancer Castrate Resist... | Abiraterone Ace... Sodium Selenite Prednisone | 18 Years - | Stanford University | |
| Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases | NCT01618370 | Prostatic Neopl... | Radium-223 dich... | 18 Years - | Bayer | |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | NCT06395519 | Advanced or Met... Breast Cancer Ovarian Cancer Prostate Cancer Epithelial Ovar... BRCA2 Mutation ER+ Breast Canc... Castrate Resist... BRCA1 Mutation BRCA Mutation Endometrial Can... Colorectal Canc... Gastric Cancer | ETX-19477 | 18 Years - | 858 Therapeutics, Inc. | |
| PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy | NCT01144897 | Castrate Resist... Prostate Cancer | PET Acetate sca... Carbon-11 label... | 18 Years - | University of Iowa | |
| Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | NCT05415098 | Nasopharyngeal ... Castrate Resist... Gastric Cancer Ovarian Clear C... Mesothelioma Sarcoma Non Hodgkin Lym... B Cell Lymphoma Epithelioid Sar... | APG-5918 | 18 Years - | Ascentage Pharma Group Inc. | |
| TT-10 as a Single Agent in Subjects With Advanced Selected Solid Tumors | NCT04969315 | Renal Cell Canc... Castrate Resist... Non Small Cell ... Head and Neck S... | TT-10 | 18 Years - | Portage Biotech | |
| A Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles In Patients With Castration-Resistant Prostate Cancer (MEL-CAP) | NCT01907009 | Castrate Resist... | Melphalan Lenograstim | 18 Years - | Barts & The London NHS Trust | |
| Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients | NCT05156372 | Prostate Cancer... Castrate Resist... Metastatic Pros... Metastatic Pros... | High Intensity ... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer | NCT01832870 | Prostate Cancer Castrate Resist... | sipuleucel-T ipilimumab | 18 Years - | Prostate Oncology Specialists, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
